Tag: LINC 2024
Aspirex achieves 78% two-year primary patency rate in P-MAX postmarket observational...
At the Leipzig Interventional Course (LINC) 2024 (28–31 May, Leipzig, Germany), Michael Lichtenberg (Arnsberg Vascular Clinic, Arnsberg, Germany) shared for the first time a...
LINC 2024: C-GUARDIANS data represent lowest event rates in published trials...
New data from the C-GUARDIANS pivotal investigational device exemption (IDE) trial support consideration of carotid artery stenting (CAS) with the CGuard embolic prevention stent...